Novo Nordisk A/S (NVO)

41.67
0.19 0.46
NYSE : Health Care
Prev Close 41.48
Open 41.54
Day Low/High 41.42 / 41.71
52 Wk Low/High 30.89 / 57.44
Volume 2.81M
Avg Volume 2.32M
Exchange NYSE
Shares Outstanding 2.55B
Market Cap 105.83B
EPS 2.00
Div & Yield 1.33 (3.20%)

Latest News

Dow Holds Lower After House Passes Health Care Vote, Crude Falls

Dow Holds Lower After House Passes Health Care Vote, Crude Falls

Stocks move mostly lower on Thursday after the House passes a bill to repeal and replace the Affordable Care Act.

Ratings Changes Today

TheStreet Quant Ratings provides fair and objective information to help you make educated investing decisions. We rate over 4,200 stocks daily and provide 5-page PDF reports for each stock. These ratings can change daily and today's changes are reflected in the email below. If you are looking to check-up on the stocks you currently own or are looking for new ideas, you can find our full database of password-protected ratings reports in our proprietary ratings screener: http://www.thestreet.com/k/qr/flat/stock-screener.html Upgrades: ANH, DVN, EXEL, FMC, FSI, GLT, MEOH, MJCO, MOH, NVO, RPXC, TECH, WU, WWE Downgrades: CIGI, IPHI, QUOT Initiations: None Read on to get TheStreet Quant Ratings' detailed report:

Novo Nordisk Launches Xultophy® 100/3.6 (insulin Degludec And Liraglutide Injection) In The United States

Novo Nordisk Launches Xultophy® 100/3.6 (insulin Degludec And Liraglutide Injection) In The United States

- New combination treatment option for adults with type 2 diabetes now available in pharmacies

Daily Earnings Round-Up

Daily Earnings Round-Up

This is your round-up of the day's earnings reports

5 Things You Must Know Before the Market Opens Wednesday

5 Things You Must Know Before the Market Opens Wednesday

U.S. stock futures decline and European shares trade lower following disappointing earnings from Apple and as Wall Street looks to Wednesday's announcement from the Federal Reserve on interest rates.

Novo Nordisk Hits 2017 High After Q1 Profit Beat, Full-Year Guidance Boost

Novo Nordisk Hits 2017 High After Q1 Profit Beat, Full-Year Guidance Boost

Novo Nordisk shares surged to a year-to-date high Wednesday after the world's biggest maker of insulin posted stronger-than-expected first quarter earnings and boosted its full-year outlook.

European Stocks Slump, Tech Sector Drifts After Apple's iPhone Miss Hits Suppliers

European Stocks Slump, Tech Sector Drifts After Apple's iPhone Miss Hits Suppliers

European stocks drifted lower as investors stepped back from a global market rally after disappointing earnings from Apple and weaker U.S. car sales put investors in a cautious mood.

Global Financial News: Apple Takes the Steam Out of the Global Equity Rally

Global Financial News: Apple Takes the Steam Out of the Global Equity Rally

European stocks slip as Apple earnings take the steam out of the global equity rally.

Bullish and Bearish Reversals for This Week

Bullish and Bearish Reversals for This Week

Financials have moved to the bearish side, this week.

Finally, People Are Bullish

Market intrigue: Utilities vs. bonds

TherapeuticsMD Hormone Pill Faces Looming FDA Rejection and a Hostile Commercial Market

TherapeuticsMD Hormone Pill Faces Looming FDA Rejection and a Hostile Commercial Market

Postmenopausal women already have a broad menu of locally administered estrogen therapy products to treat vulvar and vaginal atrophy.

What to Expect From European Pharmaceuticals' First Quarter Results

What to Expect From European Pharmaceuticals' First Quarter Results

New drug launches and late stage trials will be under the microscope as eight European pharmaceuticals companies report Q1 earnings starting next week.

Novo Nordisk Invites The Community To Unmask Everyday Heroes In Recognition Of World Hemophilia Day

Novo Nordisk Invites The Community To Unmask Everyday Heroes In Recognition Of World Hemophilia Day

#HemoHero stories to illustrate diverse experiences and inspiring acts of people affected by hemophilia

IIROC Trading Resumption - NVO

IIROC Trading Resumption - NVO

IIROC Trading Halt - NVO

IIROC Trading Halt - NVO

Delta, Barracuda Networks, STMicroelectronics: 'Mad Money' Lightning Round

Delta, Barracuda Networks, STMicroelectronics: 'Mad Money' Lightning Round

Jim Cramer is bullish on Delta, Barracuda Networks, STMicroelectronics, UnitedHealth Group.

Deregulation and Energy Policy Can Fuel Markets: Cramer's 'Mad Money' Recap (Friday 3/17/17)

Deregulation and Energy Policy Can Fuel Markets: Cramer's 'Mad Money' Recap (Friday 3/17/17)

This week the markets fell back on earnings -- like Adobe -- and remained afloat, says Jim Cramer.

SHAREHOLDER ALERT: Goldberg Law PC Announces Securities Class Action Lawsuit Against Novo Nordisk A/S And Encourages Investors With Losses To Contact The Firm

SHAREHOLDER ALERT: Goldberg Law PC Announces Securities Class Action Lawsuit Against Novo Nordisk A/S And Encourages Investors With Losses To Contact The Firm

Goldberg Law PC, a national shareholder rights litigation firm, announces the filing of a class action lawsuit against Novo Nordisk A/S (" Novo" or the "Company") (NYSE: NVO).

Egalet Makes Friday's Biotech Mailbag

Egalet Makes Friday's Biotech Mailbag

Why the name is sagging, and what it will take to spur the sector higher.

Global Blood Therapeutics Shares Jump on Report It Was Approached by Novo Nordisk

Global Blood Therapeutics Shares Jump on Report It Was Approached by Novo Nordisk

While it's not a surprise that Global Blood is a takeout target, the timing of Novo Nordisk's interest in the company comes as a surprise, according to a stock analyst.

Is This a Market Top or Just Consolidation?

Is This a Market Top or Just Consolidation?

Afternoon surge is surfacing again.

Global Blood Therapeutics Stock Surging on Nordisk Bid Speculation

Global Blood Therapeutics Stock Surging on Nordisk Bid Speculation

Global Blood Therapeutics is said to have been approached about a merger by Novo Nordisk.